ANXA13 and ovarian serous cystadenocarcinoma: The TCGA database confirmed that ANXA4 expression was downregulated in ovarian serous cystadenocarcinoma (P = 4.81E−6, fold change = − 2.019) and that ANXA13 was downregulated in malignant tumor tissues (P = 1.68E−4, fold change = − 9.347).